Literature DB >> 12673184

Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders.

Mark A Perazella1, John F Setaro.   

Abstract

The renin-angiotensin-aldosterone system (RAAS) exerts a principal influence in maintaining vascular tone, optimal salt and water homeostasis, and forward cardiac output in human beings. Overactivity of the RAAS can lead to pathologic consequences in states of diabetic nephropathy, hypertension, renal artery stenosis, left ventricular hypertrophy, coronary atherosclerosis, myocardial infarction, and congestive heart failure. In addition to fluid and hemodynamic effects, the RAAS may have a critical role in the activation of the sympathetic nervous system, the progression of atherosclerosis, the dysregulation of endothelial function, and the inhibition of the fibrinolytic system. Accumulated basic and clinical evidence supports the use of inhibitors of the RAAS, including aldosterone antagonists, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers, in treating hypertension, improving diabetic nephropathy, preventing or ameliorating congestive heart failure, and optimizing the prognosis after myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673184     DOI: 10.1067/mnc.2003.392

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  108 in total

Review 1.  Angiotensin type 2 receptors: potential importance in the regulation of blood pressure.

Authors:  H M Siragy; R M Carey
Journal:  Curr Opin Nephrol Hypertens       Date:  2001-01       Impact factor: 2.894

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 3.  Antihypertensive drug therapy and regression of left ventricular hypertrophy: a review with a focus on diuretics.

Authors:  M Moser; J F Setaro
Journal:  Eur Heart J       Date:  1991-09       Impact factor: 29.983

4.  Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance.

Authors:  J F Setaro; B L Zaret; D S Schulman; H R Black; R Soufer
Journal:  Am J Cardiol       Date:  1990-10-15       Impact factor: 2.778

5.  Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor. Comparison with effects of a beta-blocker.

Authors:  E L Schiffrin; L Y Deng; P Larochelle
Journal:  Am J Hypertens       Date:  1995-03       Impact factor: 2.689

6.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis.

Authors:  P E Tummala; X L Chen; C L Sundell; J B Laursen; C P Hammes; R W Alexander; D G Harrison; R M Medford
Journal:  Circulation       Date:  1999-09-14       Impact factor: 29.690

8.  Effects of renin-angiotensin blockade on sympathetic reactivity and beta-adrenergic pathway in the spontaneously hypertensive rat.

Authors:  A K-Laflamme; L Oster; R Cardinal; J de Champlain
Journal:  Hypertension       Date:  1997-08       Impact factor: 10.190

9.  Angiotensin II binding in area postrema and nucleus tractus solitarius of SHR and WKY rats.

Authors:  C O Andrews; J W Crim; D K Hartle
Journal:  Brain Res Bull       Date:  1993       Impact factor: 4.077

10.  Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.

Authors:  I Crozier; H Ikram; N Awan; J Cleland; N Stephen; K Dickstein; M Frey; J Young; G Klinger; L Makris
Journal:  Circulation       Date:  1995-02-01       Impact factor: 29.690

View more
  15 in total

Review 1.  Fibroblast growth factor-23: what we know, what we don't know, and what we need to know.

Authors:  Csaba P Kovesdy; Leigh Darryl Quarles
Journal:  Nephrol Dial Transplant       Date:  2013-04-25       Impact factor: 5.992

2.  Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension.

Authors:  Baojian Xue; Terry G Beltz; Yang Yu; Fang Guo; Celso E Gomez-Sanchez; Meredith Hay; Alan Kim Johnson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-26       Impact factor: 4.733

3.  Losartan renography for the detection of renal artery stenosis: comparison with captopril renography and evaluation of dose and timing.

Authors:  Emel Ceylan Günay; M Halil Oztürk; Eser Lay Ergün; Bülent Altun; Bilge Volkan Salanci; Omer Uğur; Barbaros Cil; Baki Hekimoğlu; Biray Caner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-05-05       Impact factor: 9.236

4.  Fibroblast Growth Factor 23 as Regulator of Vitamin D Metabolism.

Authors:  Shinya Nakatani; Masaaki Inaba; Ayumi Nakatani; Katsuhito Mori; Masanori Emoto; Mohammed S Razzaque
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 5.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

6.  A-6G and A-20C polymorphisms in the angiotensinogen promoter and hypertension risk in Chinese: a meta-analysis.

Authors:  Wei Gu; Jielin Liu; Qiuli Niu; Hao Wang; Yuqing Lou; Kuo Liu; Lijuan Wang; Zuoguang Wang; Jingmei Zhang; Shaojun Wen
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

7.  Genetic Variant of C-5434T REN Enhancer on Serum Renin Levels and Binding Pattern of Signal Transducers and Activators Transcription 3.

Authors:  Imama Maslahah; Mohammad Saifur Rohman; Nashi Widodo; Agustina Tri Endharti; Didik Utomo
Journal:  Int J Hypertens       Date:  2015-05-21       Impact factor: 2.420

Review 8.  Molecular targets of antihypertensive peptides: understanding the mechanisms of action based on the pathophysiology of hypertension.

Authors:  Kaustav Majumder; Jianping Wu
Journal:  Int J Mol Sci       Date:  2014-12-24       Impact factor: 5.923

Review 9.  Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.

Authors:  Gianpaolo Reboldi; Giorgio Gentile; Fabio Angeli; Paolo Verdecchia
Journal:  Vasc Health Risk Manag       Date:  2009

10.  Vitamin D levels are associated with cardiac autonomic activity in healthy humans.

Authors:  Michelle C Mann; Derek V Exner; Brenda R Hemmelgarn; Darlene Y Sola; Tanvir C Turin; Linda Ellis; Sofia B Ahmed
Journal:  Nutrients       Date:  2013-06-10       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.